Luciano Augusto Gamboa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Luciano Augusto Gamboa has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alice Grossi
Department of Molecular Medicine, Immunology and General Pathology Unit, University of Pavia, 27100 Pavia, Italy
1 shared publication - Anna Scopelliti
Department of Molecular Medicine, Immunology and General Pathology Unit, University of Pavia, 27100 Pavia, Italy
1 shared publication - Giorgia Senise
Human Physiology Unit, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy
1 shared publication - Lucia Anna Stivala
Dipartimento di Medicina Molecolare Università degli Studi di Pavia Pavia Italy
1 shared publication - Monica Savio
Immunology and General Pathology Unit, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy
1 shared publication - Samantha Solito
Centro Grandi Strumenti (CGS), University of Pavia, 27100 Pavia, Italy
1 shared publication
Latest Publications
- Open Access
- 27 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10390
Stilbene Treatment Reduces Stemness Features in Human Lung Adenocarcinoma Model
Lung cancer is among the most clinically challenging tumors because of its aggressive proliferation, metastasis, and the presence of cancer stem cells (CSCs). Natural bioactive substances have been used for cancer prevention, and, in particular, resveratrol (RSV), a stilbene-based compound with wide biological properties, has been proposed for chemoprevention. Its lesser-known analogue 4,4’-dihydroxy-trans-stilbene (DHS) has demonstrated superior activity both in cell-based assays and in mouse and zebrafish in vivo models. The present study analyzed the effects of DHS and RSV on A549 lung cancer cells, with a particular focus on stemness features and CSCs, isolated by sorting of the side population (SP). The results show that both stilbenes, especially DHS, strongly inhibited cell cycle progression. A reduction in the S phase was induced by DHS, whereas an increase in this phase was obtained with RSV. In addition, 50% reductions in the clonogenicity and soft agar colony formation were observed with the DHS treatment only. Finally, both stilbenes, especially DHS, reduced stemness marker expression in A549 cells and their sorted SP fraction. Spheroid formation, higher in SP cells than in the main population (MP), was significantly reduced after pretreatment with DHS, which was found to decrease SOX2 levels more than RSV. These findings indicate that stilbenes, and particularly DHS, affect stemness features of A549 cells and the SP fraction, suggesting their potential utility as anticancer agents, either alone or combined with chemotherapeutic drugs.
- 27 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10390
Open AccessStilbene Treatment Reduces Stemness Features in Human Lung Adenocarcinoma Model
Lung cancer is among the most clinically challenging tumors because of its aggressive proliferation, metastasis, and the presence of cancer stem cells (CSCs). Natural bioactive substances have been used for cancer prevention, and, in particular, resveratrol (RSV), a stilbene-based compound with wide biological properties, has been proposed for chemoprevention. Its lesser-known analogue 4,4’-dihydroxy-trans-stilbene (DHS) has demonstrated superior activity both in cell-based assays and in mouse and zebrafish in vivo models. The present study analyzed the effects of DHS and RSV on A549 lung cancer cells, with a particular focus on stemness features and CSCs, isolated by sorting of the side population (SP). The results show that both stilbenes, especially DHS, strongly inhibited cell cycle progression. A reduction in the S phase was induced by DHS, whereas an increase in this phase was obtained with RSV. In addition, 50% reductions in the clonogenicity and soft agar colony formation were observed with the DHS treatment only. Finally, both stilbenes, especially DHS, reduced stemness marker expression in A549 cells and their sorted SP fraction. Spheroid formation, higher in SP cells than in the main population (MP), was significantly reduced after pretreatment with DHS, which was found to decrease SOX2 levels more than RSV. These findings indicate that stilbenes, and particularly DHS, affect stemness features of A549 cells and the SP fraction, suggesting their potential utility as anticancer agents, either alone or combined with chemotherapeutic drugs.